ArticleInternational journal of general medicine2012
The discrediting of the monoamine hypothesis.
Article in International journal of general medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Review
- Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.Advances in pharmacological sciences · 2019Review
- The monoaminergic pathways and inhibition of monoamine transporters interfere with the antidepressive-like behavior of ketamine.IBRO reports · 2018Article
- Estrogen receptor β deficiency impairs BDNF-5-HTPsychoneuroendocrinology · 2017Article
- Parkinson's disease managing reversible neurodegeneration.Neuropsychiatric disease and treatment · 2016Article
- Parkinson's disease: carbidopa, nausea, and dyskinesia.Clinical pharmacology : advances and applications · 2014Article
- Management of L-dopa overdose in the competitive inhibition state.Drug, healthcare and patient safety · 2014Article
- Administration of supplemental L-tyrosine with phenelzine: a clinical literature review.Clinical pharmacology : advances and applications · 2014Review
- The Parkinson's disease death rate: carbidopa and vitamin B6.Clinical pharmacology : advances and applications · 2014Article
- Relative nutritional deficiencies associated with centrally acting monoamines.International journal of general medicine · 2012Article
- Toward a theory of childhood learning disorders, hyperactivity, and aggression.ISRN psychiatry · 2012Article
- 5-HTP efficacy and contraindications.Neuropsychiatric disease and treatment · 2012Article
Corrections and comments
- Retraction · 2020-12-16Concerns/Issues about Data · Ethical Violations by Author · Informed/Patient Consent - None/Withdrawn · Investigation by Journal/Publisher · Lack of IRB/IACUC Approval and/or Compliance · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2020-04-23Concerns/Issues about Data · Conflict of Interest · Investigation by Journal/Publisher · Updated to Retraction ·
- Expression of concern
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe monoamine hypothesis has been recognized for over half a century as a reference point to understanding electrical dysfunction associated with disease states, and/or regulatory dysfunction related to synaptic, centrally acting monoamine concentrations (serotonin, dopamine, norepinephrine, and epinephrine).
methodsOrganic cation transporters (OCT) are a primary force controlling intracellular and extracellular (including synaptic) concentrations of centrally acting monoamines and their amino acid precursors. A new type of research was analyzed in this paper (previously published by the authors) relating to determining the functional status of the nutritionally driven organic cation transporters. It was correlated with the claims of the monoamine hypothesis.
resultsResults of laboratory assays from subjects not suffering from a hyperexcreting tumor show that centrally acting monoamine concentrations are indistinguishable in subjects with and without disease symptoms and/or regulatory dysfunction. Analysis of centrally acting monoamine concentrations in the endogenous state reveals a significant difference in day-to-day assays performed on the same subject with and without monoamine-related disease symptoms and/or regulatory dysfunction. The day-to-day difference renders baseline testing in the endogenous state non-reproducible in the same subject.
conclusionIt is asserted that the monoamine hypothesis, which claims that low synaptic levels of monoamines are a primary etiology of disease, is not a valid primary reference point for understanding chronic electrical dysfunction related to the centrally acting monoamines. Furthermore, the "bundle damage theory" is a more accurate primary model for understanding chronic dysfunction. The "bundle damage theory" advocates that synaptic monoamine levels are normal but not adequate in states associated with chronic electrical dysfunction and that levels need to be increased to compensate for the chronic postsynaptic electrical dysfunction due to existing damage. The monoamine hypothesis, in failing to accurately explain the etiology of chronic neuronal electrical flow dysfunction in the endogenous state, is reduced to no more than a historical footnote.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.